Show simple item record

dc.contributor.authorMantha, S
dc.contributor.authorKarp, Rebecca Sara
dc.contributor.authorRaghavan, V
dc.contributor.authorTerrin, N
dc.contributor.authorBauer, Kenneth Alan
dc.contributor.authorZwicker, Jeffrey Isaac
dc.date.accessioned2013-03-26T20:36:45Z
dc.date.issued2012
dc.identifier.citationMantha, S, R Karp, V Raghavan, N Terrin, K A Bauer, and J I Zwicker. 2012. Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis. British Medical Journal 345:e4944.en_US
dc.identifier.issn0959-8138en_US
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:10466005
dc.description.abstractObjectives: To evaluate the risk of venous thromboembolic events associated with the use of progestin-only contraception and whether that risk differs with the mode of drug delivery (oral, intrauterine, or depot injection). Design: Systematic review and meta-analysis of randomised controlled trials and observational studies. Data sources: Pubmed, Embase, Cochrane Library, and reference lists of relevant reviews. Study selection: Randomised controlled trials and case-control, cohort, and cross sectional studies with venous thromboembolic outcome for progestin-only contraception reported relative to a non-hormone comparator group. Data extraction: Data were extracted by two independent investigators, and consensus for inclusion was reached after assessment by additional investigators. Results: Among the 2022 unique references identified by all searches, eight observational studies fulfilled inclusion criteria. A total of 147 women across all studies were diagnosed with a venous thromboembolic event while taking progestin-only contraception, and the summary measure for the adjusted relative risk of a venous thromboembolic episode for users versus non-users of a progestin-only contraceptive was, based on the random effects model, 1.03 (95% CI 0.76 to 1.39). Subgroup analysis confirmed there was no association between venous thromboembolic risk and progestin-only pills (relative risk 0.90 (0.57 to 1.45)) or a progestin intrauterine device (0.61 (0.24 to 1.53)). The relative risk of a venous thromboembolic event for users of an injectable progestin versus non-users was 2.67 (1.29 to 5.53). Conclusions: Published data assessing the risk of venous thromboembolism in women prescribed progestin-only contraception are limited. In this meta-analysis of eight observational studies, the use of progestin-only contraception was not associated with an increased risk of venous thromboembolism compared with non-users of hormonal contraception. The potential association between injectable progestins and thrombosis requires further study.en_US
dc.language.isoen_USen_US
dc.publisherBMJ Publishing Group Ltd.en_US
dc.relation.isversionofdoi:10.1136/bmj.e4944en_US
dc.relation.hasversionhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC3413580/pdf/en_US
dash.licenseLAA
dc.subjectClinical Trials (Epidemiology)en_US
dc.subjectContraceptionen_US
dc.subjectDrugs: Obstetrics and Gynaecologyen_US
dc.subjectReproductive Medicineen_US
dc.subjectVenous Thromboembolismen_US
dc.subjectSexual Healthen_US
dc.subjectInterneten_US
dc.titleAssessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysisen_US
dc.typeJournal Articleen_US
dc.description.versionVersion of Recorden_US
dc.relation.journalBritish Medical Journalen_US
dash.depositing.authorBauer, Kenneth Alan
dc.date.available2013-03-26T20:36:45Z
dc.identifier.doi10.1136/bmj.e4944*
dash.contributor.affiliatedZwicker, Jeffrey
dash.contributor.affiliatedBauer, Kenneth
dash.contributor.affiliatedKarp, Rebecca


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record